AR012304A1 - Composiciones y metodos para el tratamiento de enfermedades intestinales inflamatorias y el uso de dicha composicion para preparar medicamentos paradichos tratamientos. - Google Patents

Composiciones y metodos para el tratamiento de enfermedades intestinales inflamatorias y el uso de dicha composicion para preparar medicamentos paradichos tratamientos.

Info

Publication number
AR012304A1
AR012304A1 ARP980101486A ARP980101486A AR012304A1 AR 012304 A1 AR012304 A1 AR 012304A1 AR P980101486 A ARP980101486 A AR P980101486A AR P980101486 A ARP980101486 A AR P980101486A AR 012304 A1 AR012304 A1 AR 012304A1
Authority
AR
Argentina
Prior art keywords
compositions
treatment
treatments
composition
methods
Prior art date
Application number
ARP980101486A
Other languages
English (en)
Spanish (es)
Original Assignee
Borody Thomas J
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPO5940A external-priority patent/AUPO594097A0/en
Priority claimed from AUPO9785A external-priority patent/AUPO978597A0/en
Application filed by Borody Thomas J filed Critical Borody Thomas J
Publication of AR012304A1 publication Critical patent/AR012304A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ARP980101486A 1997-04-01 1998-04-01 Composiciones y metodos para el tratamiento de enfermedades intestinales inflamatorias y el uso de dicha composicion para preparar medicamentos paradichos tratamientos. AR012304A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPO5940A AUPO594097A0 (en) 1997-04-01 1997-04-01 Novel methods of treating inflammatory bowel disease
AUPO9785A AUPO978597A0 (en) 1997-10-14 1997-10-14 Methods of treating inflammatory bowel disease

Publications (1)

Publication Number Publication Date
AR012304A1 true AR012304A1 (es) 2000-10-18

Family

ID=25645389

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980101486A AR012304A1 (es) 1997-04-01 1998-04-01 Composiciones y metodos para el tratamiento de enfermedades intestinales inflamatorias y el uso de dicha composicion para preparar medicamentos paradichos tratamientos.

Country Status (16)

Country Link
US (1) US6277836B1 (enExample)
EP (1) EP0971735B1 (enExample)
JP (3) JP2001524951A (enExample)
AR (1) AR012304A1 (enExample)
AT (1) ATE389417T1 (enExample)
CA (1) CA2285923C (enExample)
CY (1) CY1109783T1 (enExample)
DE (1) DE69839261T2 (enExample)
DK (1) DK0971735T3 (enExample)
ES (1) ES2303351T3 (enExample)
IL (1) IL132145A (enExample)
NO (1) NO325947B1 (enExample)
NZ (1) NZ500696A (enExample)
PT (1) PT971735E (enExample)
SI (1) SI0971735T1 (enExample)
WO (1) WO1998043667A1 (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6551632B2 (en) * 1997-04-01 2003-04-22 Thomas Julius Borody Methods and compositions for treating inflammatory bowel disease
AUPP325398A0 (en) 1998-04-30 1998-05-21 Borody, Thomas J. Improved method for eradicating h. pylori
DE60043216D1 (de) * 1999-02-12 2009-12-10 Univ Washington Gm-csf zur behandlung von morbus crohn
CZ302015B6 (cs) * 1999-10-08 2010-09-08 Affinium Pharmaceuticals, Inc. Inhibitory Fab I
JP3369535B2 (ja) 1999-11-09 2003-01-20 松下電器産業株式会社 プラズマディスプレイ装置
US7638496B2 (en) 2000-02-15 2009-12-29 Valeant Pharmaceuticals North America Nucleoside analogs with carboxamidine modified monocyclic base
HRP20020781A2 (en) * 2000-03-28 2004-12-31 Biochemie Gmbh Granulated particles with masked taste
WO2002018324A2 (en) * 2000-08-29 2002-03-07 Nobex Corporation Immunoregulatory compounds, derivatives thereof and their use
JP4387804B2 (ja) * 2001-04-06 2009-12-24 アフィニアム・ファーマシューティカルズ・インコーポレイテッド ＦａｂＩ阻害剤
US8048924B2 (en) 2001-08-29 2011-11-01 Biocon Limited Methods and compositions employing 4-aminophenylacetic acid compounds
US20030118329A1 (en) * 2001-12-21 2003-06-26 Pere Obrador Video indexing using high resolution still images
AUPS088702A0 (en) * 2002-03-04 2002-03-28 Borody, Thomas Julius Electrolyte purgative
PT1575951E (pt) * 2002-12-06 2014-09-15 Debiopharm Int Sa Compostos heterocíclicos, métodos para os preparar e sua utilização em terapia
CA2519429C (en) 2003-03-17 2013-08-06 Affinium Pharmaceuticals, Inc. Pharmaceutical compositions comprising inhibitors of fab i and further antibiotics
US6930093B2 (en) * 2003-07-10 2005-08-16 Valeant Research & Development Use of ribofuranose derivatives against inflammatory bowel diseases
WO2005046567A2 (en) * 2003-09-10 2005-05-26 Meena Shelgaonkar Synergistic formulation of antioxidants and antimycobacterial agents: a method of making the same
US7417037B2 (en) 2004-01-20 2008-08-26 The Board Of Regents Of The University Of Oklahoma Compositions and methods of treatment for inflammatory diseases
NZ549661A (en) 2004-02-06 2010-07-30 Pharmatel R & D Pty Ltd As Tru Use of aminosalicylates in diarrhoea-predominant irritable bowel syndrome
JP5009152B2 (ja) * 2004-05-28 2012-08-22 サリックス ファーマシューティカルズ， インコーポレイテッド 放射線誘発性腸炎の予防、処置、および回復
WO2007053131A2 (en) 2004-06-04 2007-05-10 Affinium Pharmaceuticals, Inc. Acrylamide derivatives as antibiotic agents
EP1773767B1 (en) 2004-07-07 2016-03-09 Biocon Limited Synthesis of azo bonded immunoregulatory compounds
CN101247812A (zh) * 2005-08-24 2008-08-20 萨利克斯药品公司 巴柳氮制剂及其生产和应用
US8921344B2 (en) * 2006-11-03 2014-12-30 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
US7452872B2 (en) * 2005-08-24 2008-11-18 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
JP2009518399A (ja) * 2005-12-05 2009-05-07 アフィニウム ファーマシューティカルズ， インク． Ｆａｂｉ阻害剤および抗菌剤としてのヘテロ環アクリルアミド化合物
CA2531261A1 (en) * 2005-12-21 2007-06-21 Institut Pasteur Control of intestinal inflammatory syndromes with a preparation of killed or non infectious bacteria
EP2687533B1 (en) 2006-07-20 2017-07-19 Debiopharm International SA Acrylamide derivatives as FAB I inhibitors
WO2008098374A1 (en) * 2007-02-16 2008-08-21 Affinium Pharmaceuticals, Inc. Salts, prodrugs and polymorphs of fab i inhibitors
US8217083B2 (en) * 2007-06-08 2012-07-10 Aptalis Pharma Canada Inc. Mesalamine suppository
US8436051B2 (en) 2007-06-08 2013-05-07 Aptalis Pharma Canada Inc. Mesalamine suppository
US7541384B2 (en) 2007-06-08 2009-06-02 Axcan Pharma Inc. Mesalamine suppository
US20090098088A1 (en) * 2007-10-10 2009-04-16 The Procter & Gamble Company Methods And Kits For The Treatment Of Diverticular Conditions
JP2011500552A (ja) * 2007-10-10 2011-01-06 ルピン・リミテッド 胃腸障害を処置するための医薬用組み合わせおよび組成物
WO2009064953A1 (en) * 2007-11-15 2009-05-22 Enanta Pharmaceuticals, Inc. Use of bridged macrolides or tylosin derivatives in treating inflammatory bowel diseases
HRP20190045T1 (hr) * 2008-02-08 2019-03-08 Red Hill Biopharma Ltd. Metode i sastavi za liječenje upalne bolesti crijeva
RU2010143460A (ru) * 2008-05-01 2012-06-10 Дзе Проктер Энд Гэмбл Компани (US) Способы и наборы для терапии восстановительных состояний кишечника
WO2011044140A1 (en) * 2009-10-05 2011-04-14 Catabasis Pharmaceuticals, Inc. Substituted thioacetic acid salicylate derivatives and their uses
AU2010312309B2 (en) 2009-10-26 2016-10-06 Thomas Julius Borody Novel enteric combination therapy
US8497256B2 (en) 2010-04-26 2013-07-30 Salix Pharmaceuticals, Ltd Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives for the treatment of males
NZ611868A (en) 2010-12-13 2015-11-27 Salix Pharmaceuticals Inc Gastric and colonic formulations and methods for making and using them
TWI573590B (zh) 2011-09-20 2017-03-11 雷希爾生藥有限公司 治療自體免疫疾病之組成物及方法
HRP20190980T1 (hr) 2012-06-19 2019-08-23 Debiopharm International Sa Derivati predlijeka (e)-n-metil-n((3-metilbenzofuran-2 il)metil)-3-(7-okso-5,6,7,8-tetrahidro-1,8-naftiridin-3-il)akrilamida
EP2877163B1 (en) 2012-07-27 2019-03-20 Redhill Biopharma Ltd. Formulations and methods of manufacturing formulations for use in colonic evacuation
CA2953110C (en) * 2014-05-22 2018-10-30 John Todd Kuenstner Treatment of diseases caused by mycobacterium avium using a combination of ultraviolet blood irradiation and antibiotics
AU2017223037B2 (en) 2016-02-26 2022-04-14 Debiopharm International S.A. Medicament for treatment of diabetic foot infections
US12403131B2 (en) 2019-02-14 2025-09-02 Debiopharm International S.A. Afabicin formulation, method for making the same and uses thereof
MX2021015513A (es) 2019-06-14 2022-04-20 Debiopharm Int Sa Medicamento y uso del mismo para tratar infecciones bacterianas que involucran una biopelicula.
EP4171546A4 (en) 2020-06-30 2024-03-13 Redhill Biopharma Ltd. TRIPLE ANTIBIOTIC SOLID DOSE COMBINATION PRODUCTS, DOSAGE SCHEME, METHOD AND KITS FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS NON-TUBERCULOSIS
WO2025026423A1 (en) * 2023-08-02 2025-02-06 Shenzhen Pharmacin Co., Ltd. Compositions, their use and manufacture for treatment of gastrointestinal conditions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440763A (en) * 1981-03-18 1984-04-03 Block Drug Company, Inc. Use of 4-aminosalicyclic acid as an anti-inflammatory agent
GB8919321D0 (en) * 1989-08-25 1989-10-11 Univ London Treatment of chronic inflammatory conditions

Also Published As

Publication number Publication date
EP0971735A4 (en) 2004-02-25
JP2008024713A (ja) 2008-02-07
CY1109783T1 (el) 2013-09-04
DK0971735T3 (da) 2008-07-07
IL132145A0 (en) 2001-03-19
ATE389417T1 (de) 2008-04-15
NO325947B1 (no) 2008-08-25
CA2285923C (en) 2013-03-12
US6277836B1 (en) 2001-08-21
EP0971735B1 (en) 2008-03-19
ES2303351T3 (es) 2008-08-01
JP2012126736A (ja) 2012-07-05
IL132145A (en) 2005-11-20
WO1998043667A1 (en) 1998-10-08
JP2001524951A (ja) 2001-12-04
EP0971735A1 (en) 2000-01-19
DE69839261T2 (de) 2009-03-26
NO994778L (no) 1999-11-30
NO994778D0 (no) 1999-09-30
NZ500696A (en) 2002-05-31
PT971735E (pt) 2008-06-02
CA2285923A1 (en) 1998-10-08
DE69839261D1 (de) 2008-04-30
SI0971735T1 (sl) 2008-08-31

Similar Documents

Publication Publication Date Title
AR012304A1 (es) Composiciones y metodos para el tratamiento de enfermedades intestinales inflamatorias y el uso de dicha composicion para preparar medicamentos paradichos tratamientos.
PA8657201A1 (es) Compuestos de 3h-oxazolo y 3h-tiazolo [4, 5-d] pirimidin-2-ona 3, 5-disustituida y 3, 5, 7 - trisustituida y profarmacos de los mismos
BR0205722A (pt) Formulação de liberação prolongada e método para o tratamento de um paciente que sofre de dor
AR041725A1 (es) Prevencion, tratamiento de la enfermedad sinucleinopatica y composicion farmacologica
ES2186015T3 (es) Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol.
BRPI0412526A (pt) composto, uso de um composto, composição farmacêutica, formulação em aerossol farmacêutica, e, método para o tratamento de um paciente humano ou animal com uma condição anti-inflamatória e/ou alérgica
ES2183937T3 (es) Inhibidores de la adhesion celular.
PE20040751A1 (es) COMPOSICION FARMACEUTICA QUE COMPRENDE DOSIS BAJAS DE UN INHIBIDOR DEL TNFalfa HUMANO
ES2147294T3 (es) Compuestos terapeuticos.
BR0109912A (pt) Novas combinações antelmìnticas
MXPA05006670A (es) Administracion de capsaicinoides.
AR013001A1 (es) Derivados de la piperazina, procedimientos para prepararlos, las composiciones farmaceuticas que los contienen, su utilizacion como medicamentoy el metodo para tratar enfermedades mediadas por la taquinina.
CR7716A (es) Uso de inhibidores de la ikb-quinasa para el tratamiento del dolor
AR044050A1 (es) Utilizacion de ivermectina para el tratamiento de desordenes dermatologicos
ATE332136T1 (de) Mittel, wie nikotinamide oder cadpr zur behandlung von hautkrankheiten
ATE445389T1 (de) Liposomale glucocorticoide
ES2136252T3 (es) Tratamiento de enfermedades causadas por trastornos de la glandula sebacea mediante el uso de inhibidores de acil coa colesterol acil transferasa.
PE20040068A1 (es) Decanoato, undecanoato y dodecanoato de etonogestrel
AR049518A1 (es) Composicion farmaceutica que comprende un agente siliconado y dos principios activos solubilizados
AR045783A1 (es) Composición farmacéutica que comprende un antagonista del receptor p2x7 y una droga anti-inflamatoria no esteroide
BRPI0406858A (pt) Liberação controlada de agentes altamente solúveis
WO2004100893A3 (en) Methods for treatment of inflammatory diseases using ct-3 or analogs thereof
BR0313413A (pt) Uso da vacinação beta amilóide juntamente com um inibidor da cox-2 seletivo para o tratamento da doença de alzheimer
BRPI0407693A (pt) uso de esteróides para preparação de formulações utilizáveis no tratamento de pessoas sofrendo de distúrbios oculares, bem como formulação assim obtidos
ES2129448T3 (es) Uso de 2-(2-nitro-4-trifluorometilbenzoil)-1,3-ciclohexanodiona en el tratamiento de tirosinemia y composiciones farmaceuticas.

Legal Events

Date Code Title Description
FB Suspension of granting procedure